Northern Trust Corp Increases Stock Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Northern Trust Corp increased its stake in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) by 49.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 180,192 shares of the company's stock after buying an additional 59,902 shares during the quarter. Northern Trust Corp owned 0.42% of DiaMedica Therapeutics worth $978,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Susquehanna International Group LLP grew its holdings in DiaMedica Therapeutics by 269.5% during the fourth quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock worth $2,035,000 after buying an additional 273,395 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in DiaMedica Therapeutics by 14.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 19,339 shares of the company's stock worth $105,000 after purchasing an additional 2,380 shares during the last quarter. Barclays PLC purchased a new position in DiaMedica Therapeutics in the fourth quarter worth $151,000. Raymond James Financial Inc. purchased a new position in DiaMedica Therapeutics in the fourth quarter worth $83,000. Finally, Bank of Montreal Can purchased a new position in DiaMedica Therapeutics in the fourth quarter worth $84,000. Institutional investors own 10.12% of the company's stock.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC traded down $0.09 during trading on Friday, reaching $4.10. 89,854 shares of the stock traded hands, compared to its average volume of 82,157. DiaMedica Therapeutics Inc. has a 52-week low of $2.14 and a 52-week high of $6.82. The company has a 50-day moving average of $3.89 and a 200-day moving average of $4.98. The stock has a market capitalization of $175.82 million, a P/E ratio of -7.32 and a beta of 1.29.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, meeting analysts' consensus estimates of ($0.18). During the same period in the previous year, the firm posted ($0.14) EPS. Analysts expect that DiaMedica Therapeutics Inc. will post -0.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of DiaMedica Therapeutics in a research report on Thursday.

DiaMedica Therapeutics Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.